We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 164

Bartlett - take it up

  • Dechert LLP
  • -
  • USA
  • -
  • May 2 2012

The First Circuit decided Bartlett v. v. Mutual Pharmaceutical Co., No. 10-2277, slip op. (1st Cir. May 2, 2012) today - suggesting that it is the worst court of appeals in the country for defendants in prescription pharmaceutical product cases

Darvocet plaintiffs' Hail mary batted away

  • Dechert LLP
  • -
  • USA
  • -
  • April 25 2012

We’ve posted before about MDLs and the Darvocet MDL in particular being the new “heavyweight” division for the one-two punch of product identification (can’t sue non-manufacturers) and generic preemption (can't sue generic manufacturers) to dispose of meritless claims involving generic drugs on a large scale

If at first you don't succeed....

  • Dechert LLP
  • -
  • USA
  • -
  • April 23 2012

Sometimes good ideas don’t prevail the first time or even the first few times they make their appearance

Uninjured docs' suit tossed

  • Dechert LLP
  • -
  • USA
  • -
  • April 19 2012

Sometimes it all depends on the docs

On getting jobbed

  • Dechert LLP
  • -
  • USA
  • -
  • April 13 2012

Paradise this one isn’t

Pain pump plaintiff’s promotion-based punitives precluded

  • Dechert LLP
  • -
  • USA
  • -
  • April 12 2012

It’s déjà vu all over again

A pro-defense decision good for the digestion

  • Dechert LLP
  • -
  • USA
  • -
  • April 11 2012

As an openly defense-oriented blog, most of our posts deal with cases in which plaintiffs could not make out their claims

What a difference an MDL transfer makes

  • Dechert LLP
  • -
  • USA
  • -
  • April 6 2012

Thanks to Jim Fraser at Venable for passing along a nice fraudulent misjoinder finding in the Fosamax MDL, Welsh v. Merck Sharpe & Dohme Corp., C.A. No. 11-3045, slip op. (D.N.J. April 3, 2012

GSK citizenship issue on appeal

  • Dechert LLP
  • -
  • USA
  • -
  • April 6 2012

We can’t say much of substance about this issue, as we represent GlaxoSmithKline in certain matters, but a remedy is in sight (we hope) for the peculiar situation that has developed with respect to GSK’s citizenship for purposes of diversity jurisdiction

Generic drug preemption Q and A

  • Dechert LLP
  • -
  • USA
  • -
  • April 5 2012

There are now forty-eight post-Mensing generic drug preemption decisions on our scorecard, with more being decided on what seems like a weekly basis